Erucin （1-isothiocyanato-4-methylsulfanylbutane） is a dietary isothiocyanate produced by enzymatic hydrolysis of glucoErucin with potential cancer preventive effects, involved in apoptosis and cell cycle blockade through PARP-1 cleavage, p53 and p21，Cyp450, quinone reductase (QR), glutatione transferase (GST) and other pathways.

In LPS-stimulated RAW 264.7 macrophages, Erucin (2.5 and 5 μmol/L) inhibited NO and PGE₂ production, suppressed NF-κB activity, and reduced expression of TNF-α, IL-6, IL-1β, iNOS, and COX-2[1]. In SH-SY5Y neuroblastoma cells, Erucin (5 μM) activated the Nrf2 pathway, increased intracellular GSH levels, and protected against 6-OHDA-induced oxidative stress[2]. Erucin (30–100 μM) inhibits proliferation and migration, induces apoptosis, releases H₂S, and reduces ERK1/2 phosphorylation in AsPC-1 pancreatic cancer cells[3].

In a TPA-induced mouse ear edema model, Erucin (100 and 300 nmol) significantly reduced swelling and decreased iNOS and COX-2 expression[1].